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PRIORITY COMMUNICATIONS
Chronic Activation of Corticotropin-Releasing Factor
Type 2 Receptors Reveals a Key Role for 5-HT1A
Receptor Responsiveness in Mediating Behavioral and
Serotonergic Responses to Stressful Challenge
Adi Neufeld-Cohen, Paul A.T. Kelly, Evan D. Paul, Roderick N. Carter, Elizabeth Skinner,
Henry J. Olverman, Joan M. Vaughan, Orna Issler, Yael Kuperman, Christopher A. Lowry, Wylie W. Vale,
Jonathan R. Seckl, Alon Chen, and Pauline M. Jamieson
Background: The corticotropin-releasing factor type 2 receptor (CRFR2) is suggested to play an important role in aiding recovery from
acute stress, but any chronic effects of CRFR2 activation are unknown. CRFR2 in themidbrain raphé nucleimodulate serotonergic activity of
this key source of serotonin (5-HT) forebrain innervation.
Methods: Transgenic mice overexpressing the highly specific CRFR2 ligand urocortin 3 (UCN3OE) were analyzed for stress-related behav-
iors and hypothalamic-pituitary-adrenal axis responses. Responses to 5-HT receptor agonist challenge were assessed by local cerebral
glucose utilization, while 5-HT and 5-hydroxyindoleacetic acid content were quantified in limbic brain regions.
Results: Mice overexpressing urocortin 3 exhibited increased stress-related behaviors under basal conditions and impaired retention of
spatial memory compared with control mice. Following acute stress, unlike control mice, they exhibited no further increase in these
stress-related behaviors and showed an attenuated adrenocorticotropic hormone response. 5-HT and 5-hydroxyindoleacetic acid content
of limbic nuclei were differentially regulated by stress in UCN3OEmice as compared with control mice. Responses to 5-HT type 1A receptor
challengewere significantly and specifically reduced in UCN3OEmice. The distribution pattern of local cerebral glucose utilization and 5-HT
type 1A receptor messenger RNA expression levels suggested this effect was mediated in the raphé nuclei.
Conclusions: Chronic activation of CRFR2 promotes an anxiety-like state, yet with attenuated behavioral and hypothalamic-pituitary-
adrenal axis responses to stress. This is reminiscent of stress-related atypical psychiatric syndromes such as posttraumatic stress disorder,
chronic fatigue, and chronic pain states. This new understanding indicates CRFR2 antagonism as a potential novel therapeutic target for
such disorders.
KeyWords:Anxiety, corticotropin-releasing factor type 2 receptor,
dorsal raphé nucleus, 5-HT type 1A receptor, serotonin, stress
C orticotropin-releasing factor (CRF) plays a fundamental rolein regulating the behavioral and neuroendocrine responsesto stressors (1). Theseeffects,mediatedvia stimulationof the
CRF type 1 receptor (CRFR1) include hypothalamic-pituitary-adre-
nal (HPA) axis activation and promotion of anxiety (2). In contrast,
urocortins (Ucns) are the endogenous ligands for the CRF type 2
receptor (CRFR2) (3–7),which is suggested tomodulate these stress
responses.
Affectivedisorders are associatedwithCRFhyperactivity (8). CRF
and Ucns alter the neurotransmitter systems targeted by antide-
pressants, in particular the serotonergic system (9,10). CRFR2 is
abundant in the midbrain raphé nuclei (11–13), the main source of
serotonin (5-HT) innervation to the forebrain. CRFR2 activity in-
creases 5-HT neuronal firing rates and 5-HT release in efferent
stress-related nuclei (14–18). This interaction may provide the ma-
jor link between Ucns/CRFR2 and their effects on stress responses.
While acute pharmacologic stimulation of CRFR2 activates the
HPAaxis (19,20), both anxiogenic and anxiolytic effects onbehavior
are reported in rodents (21). Differing experimental paradigms or
nonspecificity of the pharmacologic tools employed may be re-
sponsible (6,21). Urocortin 3 (Ucn3), however, is a highly specific
agonist for CRFR2 (3,6,7). Close anatomical association between
major Ucn3 terminal fields and CRFR2 in the limbic system and
hypothalamus indicate this peptide is well placed to be an endog-
enous modulator of CRFR2 activity (22). Ucn3 appears to be anxio-
lytic when administered in acute experiments (21), but elevated
Ucn3 in the perifornical hypothalamus is anxiogenic over a period
of days (23). Although long-term CRFR2 stimulation is pertinent to
human affective disorders, the effects of chronic CRFR2 activation
on stress-related behaviors, the HPA axis, and 5-HT function are
largely unknown. We have investigated this key issue by exploiting
transgenicmiceoverexpressingUcn3 (UCN3OE)widely throughout
the brain.
Methods andMaterials
Animals
Mice overexpressing Ucn3 were generated by pronuclear DNA
microinjection of Ucn3 complementary DNA under the control of
the ROSA26 promoter into C57BL/6  BALB/c first generation
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oocytes, as previously described (24). Mice were housed in temper-
ature and lighting controlled rooms (lights on 12 hours) with free
access to laboratory chow and water. All experimental mice were
the offspring of a sire heterozygous for the transgene and a trans-
gene-negative dam from the closed colony. Thus, UCN3OE mice
were heterozygous for the transgene, and control mice were trans-
gene-negative littermates. Experiments were carried out on male
mice between 10 and 14weeks old. Principles of Laboratory Animal
Care (National Institutes of Health Publication No. 85–23, 1985)
were followed. All procedures were approved by The Salk Institute
Animal Use and Care Committee, The Weizmann Institute Animal
UseandCareCommittee, or theUnitedKingdomAnimals (Scientific
Procedures) Act, 1986.
Behavioral Testing
All tests were carried out in group-housedmice during the dark
phase of the light cycle. Mice were habituated in the home cage in
a dark room for 2 hours before testing with constant background
white noise (52 dB). For acute restraint stress, mice were subjected
to 30 minutes in a ventilated 50 mL plastic centrifuge tube and
returned to the home cage for 30 minutes before testing. Separate
cohorts of animals were used for 1) rotarod and behavioral testing
under basal conditions,n14 to 16; 2) behavioral testing following
restraint stress, n 11 to 15; and 3) Barnesmaze analysis, n 13 to
14. Order of testingwas rotarod test (cohort 1 only), open-field test,
elevated plus-maze (EPM), light-dark transfer test (LDT), and tail
suspension test (TST), with 48 to 72 hours between tests. These
animals were not further used for other experiments described in
this study.
Rotarod Test
Mice were placed on a standard rotarod apparatus with the
speed increasing linearly from 5 to 70 rpm over a 5-minute period.
Latency to fall from the rotating drumwas recorded. For evaluation
of motor skill learning, mice were tested three times in quick suc-
cession, and this was repeated three times over a period of 4 hours.
To test motor memory, another three-run cycle was performed the
following day.
Open-Field Test
The apparatus and experimental conditions were as previously
described (25). Eachmouse was placed in the center of the appara-
tus to initiate a 10-minute test session. Time spent in the inner
squares of the arena and the total number of squares crossed were
quantified.
Elevated Plus-Maze
The apparatus and experimental conditions were as previously
described (26). Number of open-arm and closed-arm entries and
time spent on the open or closed arms were scored. Arm entries
weredefined as entry of all four paws into the arm. Total armentries
were taken as an index of locomotor activity.
Light/Dark Transfer Test
The apparatus and experimental conditions were as previously
described (25). During a 5-minute test session, the latency to enter
the light compartment and the number of entries and time spent in
the light compartment were measured.
Tail Suspension Test
Mice were suspended from a metal horizontal rod by taping
by the base of the tail for 6 minutes. The duration of immobility
was scored. Anymouse climbing onto the rodwas excluded from
analysis.
Barnes Maze
The apparatus consists of a 90 cm diameter Plexiglas circular
platform, with 20 holes (5 cm diameter) equidistant around the
periphery and surrounded by visual cues. One hole leads to an
escape chamber, always located underneath the same randomly
determined hole for each mouse. The initial training session was
performedbyplacing themouse in theescapebox for 1minute and
the first trial started 1 minute later. Mice were placed in the middle
of the platform under a cup, which was removed to initiate each
trial. These were carried out with 80 dB white noise and 400 lux
lightingas aversive stimuli. The trial endeduponentry to theescape
chamber or after 5 minutes had elapsed. Sound and light were
turned off immediately upon successful termination of the trial and
the mouse was allowed to remain in the dark for 1 minute. Each
mouse was subject to 16 trials over a period of 10 days. First error
was scored as the number of holes away from the correct hole first
approached by the mouse. An error was defined as searching any
hole that did not have the escape chamber beneath it. Time to
complete the trial and the search strategy were also recorded:
random, unsystematic hole searches with crossings through the
maze center; serial, systematic hole searches (every hole or every
other hole) in a clockwise or counterclockwise direction; and spa-
tial, moving directly to the target hole or to an adjacent hole before
visiting the target. A probe test in which the escape chamber was
closed off was run on the final day. For scoring, the maze was
divided into four quadrants,with the target hole in the center of the
periphery of onequadrant. Latency to first approach the target hole
and time spent, crossings into, and the distance travelled in the
correct quadrant were scored.
Hypothalamic-Pituitary-Adrenal Axis Activity
Blood samples were collected from individually housedmice by
retro-orbital eye bleed from unanesthetized animals within 15 sec-
onds of disturbance of the home cage. For basal HPA axis activity,
samples were collected at 7:00 AM and 5:00 PM (lights on 6:00 AM).
For HPA axis response to stress, samples were collected after 2
minutes and 10 minutes of restraint stress at 7:00 AM. Individual
animals were sampled only once (n 13–15). Adrenocorticotropic
hormone (ACTH) and corticosterone levelsweremeasured in dupli-
cate in unextracted plasma samples using commercially available
radioimmunoassay kits aspreviouslydescribed (19). Adrenal glands
were weighed following dissection from a separate cohort of
animals.
Ucn3 Radioimmunoassay
Ucn3wasmeasured in whole brain (n 3) by in-house radioim-
munoassay as previously described (27).
Messenger RNA Analysis by In Situ Hybridization
Histochemistry and Quantitative Real-Time
Polymerase Chain Reaction
Antisense and sense (control) RNA probes were generated
using mouse Ucn3 complementary DNA and labeled with DIG-
11-UTP using a labeling kit from Roche Molecular Biochemicals
(Burgess Hill, United Kingdom). In situ hybridization for Ucn3
messenger RNA (mRNA) (n  3) and quantitative polymerase
chain reaction (qPCR) for CRFR1, CRFR2, and CRF mRNA expres-
sion (n  47) were carried out as previously reported (28,29).
Primers for serotonin 1A receptor (5-HT1AR) (Htr1a) qPCR: 5’-
GTGCACCATCAGCAAGGACC-3’ and 5’-GCGCCGAAAGTGGAGT-
AGAT-3’ corresponded to nucleotides 1648-1667 and 16981717,
respectively. Primers for serotonin reuptake transporter (Slc6a4)
qPCR: 5’-GGGTTTGGATAGTACGTTCGCA-3’ and 5’-CATACGCCC-
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CTCCTGATGTC-3’ corresponded to nucleotides 1490-1511 and
1650-1669, respectively (n 37).
Local Cerebral Glucose Utilization
Local cerebral glucose utilization (LCMRglc) was determined
using a 2-deoxyglucose autoradiographic imaging protocol modi-
fied from the original technique (30) as described by us previously
(31). Equal numbers (n  7) of animals from each genotype were
randomly allocated to a drug treatment group and injected (intra-
peritoneal) with either 10 mg.kg1 8-hydroxy-N,N-dipropyl-2-ami-
notetralin (8-OH-DPAT), 25 mg.kg1 1-(2,5-dimethoxy-4-iodophe-
nyl)-2-aminopropane (DOI), or vehicle (.1 mL .9% sodium chloride).
Tenminutes after injection of 8-OH-DPAT (or vehicle) or 20minutes
after injection of DOI (or vehicle) measurement of LCMRglc was
initiated by injection (intraperitoneal) of 5 Ci [14C]-2-deoxyglu-
cose in .4 mL .9% sodium chloride. After 45 minutes, mice were
decapitated and the brains processed for quantitative autoradio-
graphic imaging. Analysis of autoradiograms was performed as
described previously (32,33).
High-Performance Liquid Chromatography Analysis of Tissue
Concentrations of 5-HT and 5-Hydroxyindoleacetic Acid
Mice (n 8) were killed by decapitation under basal conditions
or 24 hours following restraint stress. Brains were stored at80°C
until analysis. Areas selected for microdissection (Table S1 in Sup-
plement 1) were identified by comparisons with a standard mouse
brain stereotaxic atlas (34) and included the raphé nuclei, an anxi-
ety-related raphé-amygdala-subiculum circuit, and septal areas im-
plicated in stress recovery. High-performance liquid chromatogra-
phy analysis of 5-HT and 5-hydroxyindoleacetic acid (5-HIAA) were
performed as previously described (35).
Statistical Analyses
Statistical analyses employed two-way analysis of variance with
post hoc analysis using Fisher’s protected least significant differ-
ence test or the two-tailed Student t test, as appropriate. Data are
presentedasmean SEM.Differenceswere considered statistically
significant at p .05.
Results
Brain Overexpression of Ucn3 in UCN3OEMice
Control brains showed endogenous Ucn3 mRNA expression in
the medial amygdala, perifornical area, and the bed nucleus of the
stria terminalis as previously reported (6,22). In situ hybridization
demonstrated widespread overexpression of Ucn3 mRNA in
UCN3OE brains (Figure 1A–G), while increased peptide levels were
confirmed by radioimmunoassay (Figure 1K). In addition to ex-
pressing Ucn3 mRNA in these endogenous sites, UCN3OE mice
have ectopic expression in numerous brain nuclei, including the
basolateral amygdala (BLA); cornu ammonis (CA)1, CA3, subiculum,
and dentate gyrus of the hippocampus; lateral septum (LS) and
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Figure 2. Mice overexpressing Ucn3 (UCN3OE) show
higher anxiety-like behavior under basal conditions. (A)
Motor performance in the rotarod test and (B) locomotor
activity in the open field test. UCN3OEmice (C) spent less
time on and (D)made fewer entries into the open arms of
the elevated plus-maze but did not differ in (E) the total
number of armentriesmade comparedwith controlmice.
In the light/dark transfer test, UCN3OEmice showed a (F)
longer latency to enter the light compartment and a
strong tendency to (G) less entries into the light and (H)
less time in the light. (I) UCN3OE mice spent more time
immobile in the tail suspension test. *p  .05, p  .06,
†p .07. n 14 to 16. Ucn3, urocortin 3.
Figure 1. Mice overexpressing urocortin 3 (UCN3OE) ex-
press Ucn3 in normal and ectopic brain nuclei. In situ
hybridization for Ucn3 messenger RNA in UCN3OE (A–G)
andcontrol (H–J)mice showedanendogenouspatternof
expression in both control and UCN3OE mice in the MeA
(E). Ectopic Ucn3messenger RNA expressionwas present
in the PAG (A),Vst (B),Ctx (C),DRN (D), BLA (E), LS andMS
nuclei (F), and the hippocampal CA1, DG, and Hb (G) of
UCN3OE mice. (J) Ucn3 peptide levels were increased in
UCN3OE brains (K). n  3. 3V, third ventricle; 4V, fourth
ventricle; Aq, cerebral aqueduct; BLA, basolateral
amygdala; CA, cornu ammonis; Ctx, cortex; DG, dentate
gyrus; DRN, dorsal raphénucleus; Hb, habenula; LS, lateral
septal; LV, lateral ventricle; MeA, medial amygdala; MS,
medial septal; PAG, periaqueductal gray; Ucn3, urocortin
3; Vst, vestibular nucleus.
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medial septum; lateral and medial habenula; caudate putamen;
piriform cortex; arcuate nucleus and ventromedial hypothala-
mus; vestibular nucleus; dorsal raphé nucleus (DRN); periaque-
ductal gray; and cortex. Several of these brain regions, including
the LS, ventromedial hypothalamus, and DRN, express high lev-
els of CRFR2 (12). CRF, CRFR1, and CRFR2 mRNA levels were
quantified in their principle sites of expression within anxiety-
related circuits (Table S2 in Supplement 1). Ucn3 overexpression
did not significantly alter their expression in any area.
UCN3OEMice Show Increased Stress-Related Behaviors
Motor learning and memory were tested using a 2-day, 12-
trial rotarod test. Mice overexpressing Ucn3 showed no motor
deficits (Figure 2A). Similarly, in the open-field test, UCN3OE
mice and littermate control mice showed no differences in total
number of crossings, indicating similar locomotor behavior (Fig-
ure 2B).
Assessment of stress-related behaviors was initially carried out
under basal conditions, without exposing mice to any stress other
than that caused by the test itself. Mice overexpressingUcn3 exhib-
ited higher anxiety-like behavior, as evidenced by less time spent
on the open arms (Figure 2C) and less entries made to the open
arms (Figure 2D) of the EPM. Again, this was not due to differences
in locomotion since the total number of entries was similar be-
tween groups (Figure 2E). In the LDT, UCN3OE mice showed in-
creased anxiety-like behavior with a longer latency to enter the
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Figure 3. Mice overexpressing uro-
cortin 3 (UCN3OE) show attenuated
behavioral responsestoacuterestraint
stress and spatial memory deficits.
UCN3OEmice(A)spentsimilartimeon
and (B)made a similar number of en-
triesintotheopenarmsoftheelevated
plus-maze as control mice. UCN3OE
mice showed a tendency to (C) a
shorter latency to enter and (D)made
significantly more entries into and (E)
spentmore time in the light compart-
ment in the light/dark transfer test. (F)
Immobility in the tail suspension test
followingstress.n11 to15. (G)Time
spent, (H) crossings in, and (I)distance
travelled in the correct quadrant and
(J) the latency to find the escape hole
during the probe test in the Barnes
maze,n13to14. *p .05, **p .01,
p .09.
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Figure 4. Mice overexpressing Ucn3 (UCN3OE) and con-
trolmice show similar basal hypothalamic-pituitary-adre-
nal axis activity but an attenuated adrenocorticotropic
hormone (ACTH) response upon acute stress. Plasma
ACTH levels were measured in the (A) evening and (B)
morning under basal conditions. (C) On acute stress,
UCN3OE mice show attenuated ACTH levels. No differ-
ences were found in plasma corticosterone levels in the
(D) evening and (E) morning or (F) following stress.
n 13 to 15. *p .05.
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light compartment (Figure 2F) and a tendency toward less entries
into the light (Figure 2G, p  .06) and less time spent in the light
(Figure 2H, p  .07). Mice overexpressing Ucn3 also spent more
time immobile than control mice in the TST (Figure 2I) (36).
It has been previously shown that activation of CRFR2 affects
anxiety-like behavior (23,37,38) under stressed conditions. Follow-
ing exposure to acute restraint stress (separate cohort), there were
no longer differences between behavior of UCN3OEmice and con-
trol mice in the EPM (Figure 3A, B; Figure S1 in Supplement 1). This
appears due to a stress-related increase in anxiety-like behavior in
control butnotUCN3OEmice. In theLDT,UCN3OEmiceentered the
light compartment more often (Figure 3D) and spent significantly
more time in the light (Figure 3E) than control mice. This appeared
to be due to a decrease in anxiety-like behavior in UCN3OEmice.
Stress increased immobility in the TST in both genotypes, but
there was no difference between genotypes in immobility fol-
lowing stress (Figure 3F). Overall stress removed the affective
behavioral differences between UCN3OE and control mice seen
under basal conditions.
Spatial Learning andMemory in the Barnes Maze
Both control and UCN3OE mice showed similar learning in the
Barnesmaze (39), as shown bymeasures of reduction in distance of
the first hole checked from the escape hole (first error), reduction in
number of errors made in each trial set, shorter latency to escape
over 16 trials, and the strategy used to locate the escape hole
(Figure S1 in Supplement 1). Retention of learningwas tested using
a single trial probe test. Mice overexpressing Ucn3 explored the
correct quadrant significantly less than control mice, as shown by
the number of crossings (Figure 3H) and distance travelled (Figure
3I) in the correct quadrant. In addition, UCN3OE mice showed a
longer latency to approach the escape hole (Figure 3J). Hence,
UCN3OE mice show impaired spatial memory retention.
HPA Axis Responsiveness
ACTH and corticosterone levels measured under stress-free
basal conditionswere not different between genotypes at the diur-
nal peak (Figure 4A, D) and trough (Figure 4B, E) of the circadian
rhythm. Following restraint stress, UCN3OE mice showed a signifi-
Table 1. LCMRglc in Brain Regions of Control and UCN3OE Mice in Response to 5-HT1AR Agonist 8-OH-DPAT
Control UCN3OE
Saline 8-OH-DPAT % Saline 8-OH-DPAT %
Dorsal Raphé Nucleus 35  3 25  3a 29 33  3 18  5a 46
Median Raphé Nucleus 46 2 36  3a 22 45  3 24  7a 47
Neocortex
Orbitofrontal 62  4 39  4a 37 62  5 52  4 16
Frontal 46 3 33  3a 28 48  4 42  3 12
Anterior cingulate 48 4 31  4a 36 45  5 39  4 13
Prefrontalb,c 47  5 22  3a 53 47  4 42  2 11
Somatosensory 54  4 38  5a 29 52  5 45  3 13
Parietal 54  4 34  4a 35 48  5 43  3 10
Posterior cingulate 51 4 32  3a 37 49  5 42  2 15
Piriform 39  3 24  2a 38 41  3 35  5 14
Entorhinal 35  3 24  3a 32 33  2 29  2 12
Hippocampus
Molecular layerb 41  4 26  3a 38 44  3 38  2 14
Dorsal subiculumb,c 38  3 24  3a 39 36  3 32  2 11
Dentate gyrusc 25  1 15  1a 38 23  2 20  1 13
Dorsal CA1 35 3 23  4a 36 33  2 28  3 15
CA2 33  3 21  2a 36 34  3 30  4 12
Ventral CA1 33 2 20  2a 39 31  3 27  2 13
Ventral subiculum 29 2 20  2a 31 28  3 25  3 11
CA3 33  2 16  2a 52 34  2 29  1 15
Extrapyramidal Areas
Medial striatum 43 3 33  3a 24 44  3 39  2 11
Lateral striatumc 48  4 29  3a 39 46  3 41  3 11
Globus pallidus 32 3 22  1a 31 33  2 29  2 12
Substantia nigra, reticulata 31 2 22  2a 29 33  2 28  3 15
Substantia nigra, compacta 37 3 27  1a 28 39  2 34  3 13
Limbic Areas
Medial septal nucleusb 42  2 29  3a 31 45  3 38  2 16
Lateral septal nucleus 34 3 22  3a 35 36  4 26  2a 27
Bed nucleus of the stria terminalis 28 3 17  2a 41 28  2 20  3a 29
Basolateral amygdala 36 3 22  3a 39 34  3 30  3 12
Central amygdala 23 3 17  2 26 25  2 22  3 12
LCMRglc shown as mean  SEM and % change in LCMRglu in DOI compared with saline-treated mice. n  7. There was a main effect of 8-OH-DPAT
treatment for all brain areas.
CA, cornu ammonis; 5-HT1AR, serotonin 1A receptor; LCMRglc, local cerebral glucose utilization; UCN3OE, mice overexpressing urocortin 3.
ap .05 versus saline.
bMain effect of genotype.
cMain effect of genotype 8-OH-DPAT treatment.
A. Neufeld-Cohen et al. BIOL PSYCHIATRY 2012;72:437–447 441
www.sobp.org/journal
cantly attenuated rise in ACTH levels over 10 minutes (Figure 4C),
although the rise in corticosterone levels over this time was similar
to control mice (Figure 4F). Total adrenal weight did not differ from
control mice (control mice 3.62 .27 mg, UCN3OE 3.69 .33 mg,
n 6–8).
Serotonergic Function Is Altered in UCN3OEMice
Following challenge with the 5-HT1AR-specific agonist
8-OH-DPAT, analysis of variance revealed amain effect of treatment
in all brain areas examined and of genotype in the hippocampal
CA3 [F (1,24)15.082,p .01] andmolecular layer [F (1,24)5.921,
p .05], prefrontal cortex [F (1,24) 7.407, p .05], dorsal subicu-
lum [F (1,24)  4.645, p  .05], and the medial septum [F (1,24) 
5.538, p .05] (Table 1 and Table S3 in Supplement 1). There was a
significant interaction of treatment  genotype in the hippocam-
pal CA3 [F (1,24)  11.081, p  .01], prefrontal cortex [F (1,24) 
7.407, p .05], dorsal subiculum [F (1,24) 8.258, p .01], dentate
gyrus [F (1,24)  4.902, p  .05], and lateral striatum [F (1,24) 
4.558, p .05]. In contrast, when challenged with the serotonin 2C
receptor-specific agonist DOI, despite a main effect of treatment in
many brain areas, ranging from hippocampal field CA3 [F (1,24) 
33.923] to parietal cortex [F (1,24) 11.461], there was nomain effect
of genotype or any significant interaction of genotypewith treatment
on LCMRglc (Table 2 and Table S4 in Supplement 1), demonstrating a
differential response to 8-OH-DPAT only between genotypes.
Further post hoc analysis (Tables 1 and 2) revealed no significant
differences in LCMRglc between vehicle-treated control and
UCN3OE mice, indicating no effect of genotype on constitutive
cerebral glucose utilization, likely reflecting adaptation to lifelong
altered function. Following 8-OH-DPAT, the decrease in LCMRglc
was significantly less than in controlmice, and, in fact, LCMRglcwas
not different from vehicle-treated animals in the majority of brain
regions studied, indicating an attenuated response to 5-HT1AR
stimulation. In contrast, when challenged with DOI, there was no
significant difference in LCMRglc between the genotypes (Table 2).
Messenger RNA expression of the 5-HT1AR was significantly de-
creased in the DRN and amygdala of the UCN3OE mice (Figure 5;
Figure S2 in Supplement 1). Serotonin reuptake transporter mRNA
expression did not differ between genotypes in any brain region
examined.
Consistent with the observation of unchanged constitutive
brain function inUCN3OEmice, therewas nodifference in 5-HT and
Table 2. LCMRglc in Brain Regions of Control and UCN3OE Mice in Response to 5-HT2CR Agonist DOI
Control UCN3OE
Saline DOI % Saline DOI %
Dorsal Raphé Nucleus 36  3 37  2 3 33  5 30  3 9
Median Raphé Nucleus 45  5 46  3 2 45  3 44  3 2
Neocortex
Orbitofrontala 58  3 47  2b 19 63  5 50  3b 21
Frontala 43  2 36  1b 16 45  3 34  3b 24
Anterior cingulatea 46  2 39  2b 16 48  3 38  2b 21
Prefrontala 44  3 33  3b 20 47  4 36  2b 23
Somatosensory 51  4 47  4 8 55  6 53  3 4
Parietala 54  3 42  4b 22 54  5 40  3b 26
Posterior cingulate 49  2 48  2 2 52  4 52  2 0
Piriform 40  3 33  2 14 43  3 39  5 10
Entorhinal 37  3 32  1 13 35  2 32  3 9
Hippocampus
Molecular layera 42  3 34  2b 19 46  3 35  2b 24
Dorsal subiculum 40  3 44  2 10 37  3 36  3 3
Dentate gyrusa 26  2 16  2b 38 24  2 15  1b 38
Dorsal CA1a 37  3 25  3b 32 38  3 28  2b 26
CA2 35  3 36  4 3 32  3 30  3 6
Ventral CA1 34  2 30  2 13 31  3 29  2 6
Ventral subiculum 30  2 30  4 0 33  2 35  3 6
CA3a 34  2 24  2b 29 36  2 25  1b 31
Extrapyramidal Areas
Medial striatuma 41  3 31  2b 24 42  3 30  2b 22
Lateral striatuma 46  3 29  3b 36 44  3 31  3b 30
Globus pallidus 30  2 32  2 7 33  2 32  3 3
Substantia nigra, reticulata 29  2 30  2 3 28  2 28  4 0
Substantia nigra, compacta 36  2 37  3 2 34  3 34  3 0
Limbic Areas
Medial septal nucleus 40  2 38  3 5 38  3 38  2 0
Lateral septal nucleus 34  3 33  3 3 37  4 36  2 2
Bed nucleus of the stria terminalis 27  3 27  2 0 25  6 27  3 8
Basolateral amygdala 33  2 28  4 15 34  5 30  3 12
Central amygdala 22  2 18  2 18 25  2 22  3 12
LCMRglc shown as mean SEM and % change in LCMRglu in DOI compared with saline-treated mice. n 7. There was no main effect of genotype or
interaction of genotype DOI treatment for any brain area.
CA, cornu ammonis; 5-HT2CR, serotonin 2C receptor; LCMRglc, local cerebral glucose utilization; UCN3OE, mice overexpressing urocortin 3.
aMain effect of DOI treatment.
bp .05 versus saline.
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5-HIAA content of selected brain nuclei when compared with con-
trol mice under basal conditions (Figure 6; Table S5 in Supplement
1). There were significant main effects of stress on 5-HT content in
the caudal DRN [F (1,28)  7.566, p  .05], dorsal DRN [F (1,28) 
8.477, p .01], and the BLA [F (1,28) 4.337, p .05]. For 5-HIAA,
there was a significant main effect of stress in the caudal DRN
[F (1,28)  13.278, p  .01] and dorsal DRN [F (1,28)  10.495, p 
.01]. Therewas a significant interaction (genotype stress) onboth
5-HT [F (1,28) 4.225, p .05] and 5-HIAA [F (1,28) 5.371, p .05]
concentrations in the intermediate LS.
Post hoc analysis revealed that 24 hours following a stressor,
there was an increase in 5-HIAA content of the caudal DRN (Figure
6A) of control mice. In contrast, UCN3OE mice showed a more
robust serotonergic responsewith significant increases in 5-HT and
5-HIAA in both the caudal and dorsal DRN poststress (Figure 6A, B).
They also showed decreased 5-HIAA, in the intermediate LS post-
stress (Figure 6C). Therewere no effects of stress or genotype in the
central amygdala, medial septum, or subiculum (data not shown).
Discussion
We show that specific CRFR2 activation by chronic Ucn3 overex-
pression increases baseline stress-related behaviors and yet atten-
uates the affective impacts of stress and aspects of HPA axis func-
tion. The underlying mechanism for this is plausibly reduced
5-HT1AR signaling in the raphé nuclei.
Ucn3 overexpression should result in continuous and chronic
stimulation and relative hyperactivation of CRFR2. Ucn3 overex-
pressionhas potential to stimulate endogenousCRFR2 at the site of
expression, e.g., in the LS, BLA, hippocampal CA1, and the DRN
(12,13), or to exert effects via axonal transport of Ucn3 to CRFR2
fields, e.g., the habenula has no CRFR2 but provides projections to
the DRN (40–42). Importantly, CRFR2 levels in functionally signifi-
cant sites, including the paraventricular nucleus, LS, median raphé
nucleus (MRN), and DRN, are not affected by the continuous over-
expression of ligand, a finding in keepingwith unaltered peripheral
expression of CRFR2 in these mice (24).
Mice overexpressing Ucn3 display an increase in stress-related
behaviors under basal circumstances, suggesting chronic CRFR2
activation promotes an anxiety-like state. This extends and accords
with the previously observed increase in anxiety seen following
viral overexpression of Ucn3 in hypothalamus (23). Anxiety impairs
spatial memory (43–48), plausibly accounting for the reduced re-
tention of the spatial memory seen in UCN3OE mice. Conversely,
following a stressor, indices of anxiety-like behavior and immobility
in the TST in UCN3OE mice were similar to or lower than in control
mice. This could be due to a ceiling effect of the enhanced anxiety
levels in the UCN3OE mice. However, UCN3OE mice even showed
some anxiolysis under stressful conditions. Overall, CRFR2 hyperac-
tivation in this model displays a dual and contrasting effect under
basal and stress conditions, in agreement with the suggested roles
of CRFR2 in contributing to the recovery phases of the stress re-
sponse (49–51). These effects may be, at least in part, due to direct
effects of CRFR2 stimulationbyUcn3onbehavior. However, current
understanding of CRFR2 function in relation to this aspect has
moved mechanistic theories away from the originally proposed
direct opposition of CRFR1 action and toward more complex regu-
lation of other neurotransmitter systems by CRFR2 activity, in par-
ticular 5-HT function (15,16,29,52). Consistent with this, 5-HT func-
tion is significantly altered in UCN3OE mice, with evidence of
attenuated 5-HT1AR responsiveness.
The response to a 5-HT1AR agonist was altered in extrapyrami-
dal brain areas lacking in 5-HT1AR (53,54) but which receive 5-HT
projections from the DRN (55,56) in UCN3OE mice, inferring the
effect ismediated in theDRN rather than in the forebrain structures
themselves. Serotonin innervation of the forebrain is supplied by
the MRN and DRN (57), both of which express CRFR2 (12), and it is
likely the MRNmay be similarly affected. However, 5-HT1ARmRNA
expression and 5-HT and 5-HIAA content following stress exposure
were altered only in the DRN of UCN3OEmice, suggesting this may
be the main site where effects on 5-HT function by CRFR2 are
mediated. In keepingwith this, 5-HT1ARwas downregulated in the
UCN3OE amygdala, an areawhere 5-HT projections are supplied by
the DRN (57).
Mice overexpressing Ucn3 show enhanced stress-induced 5-HT
and 5-HIAA content in the DRN, consistent with their attenuated
response to 5-HT1AR agonist and reduced 5-HT1AR expression
here, as less autoinhibition by 5-HT1AR correlates with increased
activation and firing rates of 5-HT neurons. While the dorsal DRN is
the classic anxiety-related subregion of the DRN activated by anx-
iogenic drugs, social defeat, fear-potentiated startle, and urocortin
2 (15,58–60), the caudal DRN may mediate stress-induced altera-
tions of 5-HT in forebrain regions including the LS (61). Adifferential
genotype effect in the LS was also observed, with decreased 5-HT
and 5-HIAA levels in UCN3OE mice poststress. This area not only
receives both DRN and MRN projections but is also implicated in
promoting stress-related behaviors mediated by direct activation
of the CRFR2 expressed here (62,63).
Corticotropin-releasing factor receptor stimulation in the raphé
nuclei regulates efferent 5-HT release in a site-specificmanner with
increases in cortex and hippocampus but decreases in other re-
gions including the LS and striatum (10). This is presumed due to
differential CRFR1 versus CRFR2 activation (9). Our results implicate
CRFR2 in modulating these effects following a stressor. In contrast,
nodifference in the 5-HT responses ofUCN3OEmice in amygdala or
Figure 5.Mice overexpressing Ucn3 (UCN3OE) show decreased basal htr1a
messenger RNA expression within the (A) dorsal raphé nucleus (DRN) and
(C) amygdala but not (B)median raphé nucleus (MRN) or (D) hippocampus.
Basalhtr1a and slc6a4messenger RNAexpressionwithin stress-relatedbrain
regions in mice overexpressing urocortin 3 and control mice. Panels on the
right depict the location of the tissue dissection. n 4 to 7, except for MRN
n 3 to 4. **p .01.
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subiculum compared with control mice indicates this anxiety-re-
lated circuit may not be key to their stress-related phenotype or,
given the well-documented effects of stress here, that 24 hours is
not the crucial time point to observe any differential effects.
Dysregulated 5-HT functioning is recognized to underlie the
pathophysiology of stress-related psychopathologies, including
anxiety disorders and depression, with decreased 5-HT1AR activity
associated with these disorders (64–66). Learned helplessness, a
behavioral model for anxiety and affective disorders, is dependent
on 5-HT activity in the DRN and is proposed to result from hyperac-
tivation of 5-HT neurons in the DRN during exposure to uncontrol-
lable stress (67), leading to internalizationof inhibitory serotonin1A
autoreceptors, thus sensitizing other DRN 5-HT neurons to subse-
quent stress (68,69). In addition tomodulating 5-HT neuronal activ-
ity, CRFR2 stimulation mediates the behavioral aspects of this pro-
cess (70). Thus, we hypothesize the phenotype of theUCN3OEmice
is a consequence of the continued activation of CRFR2 resulting in a
similar process. We propose a model where in the healthy animal,
Ucn3 is rapidly released in response to an acute stressor (19,71) and
is an important mediator of the stress recovery process (51). How-
ever, in UCN3OE mice, ongoing Ucn3 stimulation of CRFR2 models
a chronically stressed animal with increased anxiety-like behaviors
and decreased responsiveness of 5-HT1AR autoreceptors.
Contrary to what might be anticipated given their behavioral
phenotype, UCN3OE mice showed no differences in ACTH or corti-
costerone levels under basal conditions but exhibited attenuated
Figure 6. Mice overexpressing Ucn3 (UCN3OE) show stress-induced alterations in tissue concentration of serotonin (5-HT) and 5-hydroxyindoleacetic acid
(5-HIAA) levels in stress-related brain regions. 5-HT (left panel) and 5-HIAA (middle panel) concentrations under unstressed and 24 hours poststress (24h)
conditions in the (A) dorsal raphé nucleus, caudal part (DRC), (B) dorsal raphé nucleus, dorsal part (DRD), (C) lateral septum, intermediate part (LSI), and (D)
basolateral amygdala (BLA). Panels on the right depict the location of the microdissection and approximate distance from bregma (reprinted from Paxinos
and Franklin [34] with permission from Elsevier, copyright 2001). n 8. Scale bar 1 mm. *p .05; **p .01. Ucn3, urocortin 3.
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HPA axis activation (ACTH) in response to stress. Adrenal weight
and corticosterone response to stress were not different between
genotypes, suggesting possibly greater adrenocortical responses
to ACTH in UCN3OEmice, butmore detailed analyses over a longer
time course are required to draw any definite conclusions.
Blunting of ACTH responses is observed in a subgroup of affec-
tive disorders, including atypical depression, posttraumatic stress
disorder, and in adults following childhood abuse (72–74), andHPA
axis hyporeactivity has been reported in rodents exposed tomater-
nal separation (75–77). Proposed mechanisms include desensitiza-
tion of CRF receptors and hence the HPA axis by chronically ele-
vated ligand (78) or hypoactivity of CRF neurons based on findings
of low CRF in cerebrospinal fluid in patients in certain disorders
including chronic fatigue and atypical depression (79–82). In either
case, this would appear to be a maladaptation to chronic stress
exposure.
Therefore, while attenuated HPA axis and behavioral responses
to stress may well reflect the proposed contrasting role of CRFR2
under basal and stressed conditions (49,50), they may also repre-
sent maladaptation of the stress response, akin to that observed in
illnesses such as atypical depression and posttraumatic stress dis-
order. Atypical depression has been reported to have a higher
comorbidity of anxiety disorders than other subtypes of depression
(83,84). Furthermore, gender differences in clinical presentation,
with women reported to show more atypical and anxiety symp-
toms than men (85–87), have led to suggestions that similar sero-
tonergic dysfunctioning underpins both atypical depression and
anxiety disorders and that selective serotonin reuptake inhibitors
may be more effective than other antidepressant medications in
women. Our findings in UCN3OEmice provide further evidence for
this link between anxiety, hyporesponsiveness of the HPA axis, and
associated dysregulation of serotonergic function, specifically at-
tenuated 5-HT1AR responsiveness. Thus, the role of CRFR2 and
urocortins in relation to these psychiatric conditions appears wor-
thy of further study. There is much to be elucidated regarding the
complex regulation of serotonergic function by CRFR2, and
UCN3OE mice may provide a useful model in this respect.
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